Olaratumab (Lartruvo)

OFFICE ADMINISTRATION

FDA Approved Indication:
  • Indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery
Patients must meet the following criteria for the indication above:
  • Prescribed by an oncologist, AND
  • Patient is at least 18 years of age, AND
  • Medical record documenation confirms diagnosis of soft tissue sarcoma with a histologic subtype for which an anthracyline-containing regimen is appropriate and not amenable to curative treatment with surgery or radiotherapy, AND
  • Lartruvo will be administered with doxorubicin for the first 8 cycles
Dosing:
  • 15 mg/kg as an intravenous infusion over 60 minutes on Days 1 and 8 of each 21-day cycle
  • For the first 8 cycles, Lartruvo is administered with doxorubicin
  • Premedicate with diphenhydramine and dexamethasone IV, prior to Lartruvo on Day 1 of cycle 1

Approval:

  • One year